1073545-59-1

Upstream product

• 865233-82-5 2,2-Dimethyl-5-[4-(tetrahydro-pyran-2-yloxy)-benzylidene]-[1,3]dioxane-4,6-dione 
• 115062-69-6 5-[[4-[(4-methoxyphenyl)methoxy]phenyl]methylene]-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 77182-73-1 4-[(4-methoxyphenyl)methoxy]benzaldehyde 
• 123-08-0 4-hydroxy-benzaldehyde 
• 865232-10-6 C₂₀H₂₂O₄ 
• 1073545-57-9 ethyl 4-methyl-3-(4-(tetrahydro-2H-pyran-2-yloxy)phenyl)-4-pentenoate 

Downstream Products

• 1073545-63-7 ethyl (3S)-(4-hydroxyphenyl)-4-methyl-4-pentenoate 
• 1073545-61-5 ethyl (3R)-(4-hydroxyphenyl)-4-methyl-4-pentenoate 
• 1073545-69-3 ethyl (3S)-3-(4-(((6-(1,1-dimethylethyl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-3-yl)methyl)oxy)phenyl)-4-methyl-4-pentenoate 
• 1073545-65-9 ethyl (3R)-3-(4-(((6-(1,1-dimethylethyl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-3-yl)methyl)oxy)phenyl)-4-methyl-4-pentenoate 
• 1073543-90-4 (3S)-3-(4-(((6-(1,1-dimethylethyl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-3-yl)methyl)oxy)phenyl)-4-methyl-4-pentenoic acid 
• 1073543-86-8 (3R)-3-(4-(((6-(1,1-dimethylethyl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-3-yl)methyl)oxy)phenyl)-4-methyl-4-pentenoic acid 

Relevant academic research and scientific papers

AMG 837: A potent, orally bioavailable GPR40 agonist

The discovery that certain long chain fatty acids potentiate glucose stimulated insulin secretion through the previously orphan receptor GPR40 sparked interest in GPR40 agonists as potential antidiabetic agents. Optimization of a series of β-substituted p

SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula (I) where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.